| Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments. | |
| | |
MedLine Citation:
|
PMID: 20618466 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Progressive Multifocal Leukoencephalopathy (PML) is a rare and often fatal opportunistic demyelinating disorder secondary to central nervous system infection by the polyomavirus John Cunningham (JC), a common infecting agent in human populations, with 50-70% of healthy individuals having antibodies to the virus. Although human immunodeficiency virus (HIV) infection remains the most common predisposing factor for PML, which can occur also in association with hematologic malignant neoplasms or iatrogenic immunosuppression in the setting of organ transplantations, recently JC virus has been recognized as an important pathogen in patients with autoimmune and rheumatic diseases receiving immunosuppressive treatments. Following the availability of new biologic drugs, additional cases of PML have been reported in dermatologic patients as well. In particular, the occurrence of PML in psoriatic patients who had been taking efalizumab in the absence of any other concurrent immunosuppressive agents resulted in the decision of European Medicine Agency (EMEA) in February 2009 to recommend suspension of the marketing authorization for this drug in Europe. Some months later the manufacturer of the drug decided to voluntarily withdraw the product from the U.S. market. Since PML can occur as a potential side effect of different immunosuppressive drugs, including conventional treatments for psoriasis, and in consideration of the future development of new immunosuppressive biological agents, dermatologists need to become familiar with opportunistic infections including PML. |
| | |
Authors:
|
Vito Di Lernia |
Related Documents
:
|
19358236 - T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gr... 18360256 - Impact of immunosuppressive drugs on cd4+cd25+foxp3+ regulatory t cells: does in vitro ... 10451066 - Risk of developing certain malignancies is related to duration of immunosuppressive dru... 2190256 - Pharmacology of nootropics and metabolically active compounds in relation to their use ... 22307316 - Spectral deciphering of the interaction between an intramolecular hydrogen bonded esipt... 16231966 - Clinical pharmacokinetics of cyclophosphamide. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: International journal of dermatology Volume: 49 ISSN: 1365-4632 ISO Abbreviation: Int. J. Dermatol. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-07-12 Completed Date: 2010-10-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0243704 Medline TA: Int J Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 631-5 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy. vito.dilernia@asmn.re.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
administration & dosage,
adverse effects* Humans Immunosuppressive Agents / administration & dosage, adverse effects* Leukoencephalopathy, Progressive Multifocal / epidemiology, etiology*, immunology Psoriasis / drug therapy*, epidemiology Risk Assessment Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/efalizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: UVA1 phototherapy: a review of mechanism and therapeutic application.
Next Document: Life events involvement in psoriasis onset/recurrence.